ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

作者：Wilson James M; Fokas Emmanouil; Dutton Susan J; Patel Neel; Hawkins Maria A; Eccles Cynthia; Chu Kwun Ye; Durrant Lisa; Abraham Aswin G; Partridge Mike; Woodward Martha; O'Neill Eric; Maughan Tim; McKenna W Gillies; Mukherjee Somnath^*; Brunner Thomas B

来源：Radiotherapy and Oncology, 2016, 119(2): 306-311.

DOI：10.1016/j.radonc.2016.03.021

• Nelfinavir
• Trial
• Pancreatic cancer
• Hypoxia
• Imaging
• Radiosensitisation

Background and purpose: Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC).
Materials and methods: Radiotherapy (50.4 Gy/28 fractions; boost to 59.4 Gy/33 fractions) was administered with weekly gemcitabine and cisplatin. Nelfinavir started 3-10 days before and was continued during CRT. The primary end-point was 1-year overall survival (OS). Secondary end-points included histological downstaging, radiological response, 1-year progression free survival (PFS), overall survival (OS) and treatment toxicity. An imaging sub-study (n = 6) evaluated hypoxia (F-18-Fluoromisonidazole-PET) and perfusion (perfusion CT) during induction nelfinavir.
Results: The study closed after recruiting 23 patients, due to non-availability of Nelfinavir in Europe. The 1-year OS was 73.4% (90% CI: 54.5-85.5%) and median OS was 17.4 months (90% CI: 12.8-18.8). The 1 year PFS was 21.8% (90% CI: 8.9-38.3%) and median PFS was 5.5 months (90% CI: 4.1-8.3). All patients experienced Grade 3/4 toxicity, but many were asymptomatic laboratory abnormalities. Four of 6 patients on the imaging sub-study demonstrated reduced hypoxia and increased perfusion post-nelfinavir.
Conclusions: CRT combined with nelfinavir showed acceptable toxicity and promising survival in pancreatic cancer.

• 出版日期2016-5